← Back to Clinical Trials
Recruiting NCT07500324

NCT07500324 Proteomic Biomarker Identification in AMD, Diabetic Retinopathy and Retinal Detachment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07500324
Status Recruiting
Phase
Sponsor Fondazione G.B. Bietti, IRCCS
Condition Age-Related Macular Degeneration (AMD)
Study Type INTERVENTIONAL
Enrollment 260 participants
Start Date 2024-01-24
Primary Completion 2027-01

Trial Parameters

Condition Age-Related Macular Degeneration (AMD)
Sponsor Fondazione G.B. Bietti, IRCCS
Study Type INTERVENTIONAL
Phase N/A
Enrollment 260
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-01-24
Completion 2027-01
Interventions
Biological Sample Collection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal detachment (RD). A total of approximately 260 participants (cases and controls) will be enrolled at a single center. Biological samples, including peripheral blood, tears, aqueous humor, vitreous humor, and subretinal fluid, will be collected during routine clinical and surgical procedures. Advanced clinical proteomics approaches will be applied to characterize molecular signatures associated with disease onset, progression, and response to treatment. The study seeks to improve the understanding of disease pathophysiology and support the development of novel diagnostic and prognostic biomarkers in ophthalmology.

Eligibility Criteria

Inclusion Criteria: Age ≥ 18 years Ability to understand the study procedures and provide written informed consent Willingness and ability to comply with study procedures and visits For case subjects: Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD) Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema) Patients undergoing surgery for primary or recurrent retinal detachment For control subjects: Patients scheduled for cataract surgery with no documented retinal diseases (e.g., AMD, diabetic retinopathy, retinal vascular occlusions, or retinal epithelial disorders) Outpatients with no documented retinal diseases For retinal detachment subgroup: patients undergoing macular surgery (e.g., macular pucker or macular hole) or cataract surgery with attached retina Exclusion Criteria: Age \< 18 years Presence of infectious ocular diseases Alterations in the electro

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology